Objectives. We sought to identify predictors of lead concentrations in the blood, tibias, and patellae of older adults and to describe differences by gender, race/ ethnicity, and other factors that can influence lead toxicokinetics and, thus modify health effects.
Gender and Race/Ethnicity Differences in Lead Dose Biomarkers | Keson Theppeang, MHS, Thomas A. Glass, PhD, Karen Bandeen-Roche, PhD, Andrew C. Todd, PhD, Charles A. Rohde, PhD, and Brian S. Schwartz, MD (SES). 6, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Although other studies have documented differences in blood lead concentrations by race/ethnicity and SES, 2, 28, 29 these studies did not simultaneously measure bone lead concentrations. No population-based studies have compared the bone lead concentrations of large numbers of African Americans and Whites, and no studies have included participants across the full spectrum of SES. Understanding differences in bone lead concentrations in blood, tibias, and patellae across sociodemographic groups may contribute to an explanation of persistent and widening health disparities. 28, [30] [31] [32] This could lead to interventions to prevent or lessen the health risks associated with lead in late life. We examined lead concentrations and from our analysis determined predictors of blood, tibia, and patella lead concentrations in a population-based study of community-dwelling urban residents aged 50 to 70 years with diversity by gender, race/ethnicity, and SES.
METHODS Study Population and Design
The study design, population, and assessment methods for the Baltimore Memory Study (BMS) have been previously reported. 33 In brief, the BMS is a prospective study of 1140 urban residents, aged 50 to 70 years. Participants were selected by stratified random sampling from 65 contiguous neighborhoods in central and north Baltimore, Maryland. All participants were scheduled for 3 visits at approximately 14-month intervals; 1022 (89.6%) completed the second visit, and 943 (82.7%) completed the third visit. Of the 197 who did not return for the third visit, 101 (9% of those enrolled) refused, 23 (2%) were too ill, 21 (2%) were deceased, 38 (3%) were lost to follow-up, and 14 (1%) had moved out of state. There was no evidence of selective dropout by age, gender, race/ethnicity, education, or wealth (all P > .05 by χ 2 or analysis of variance). All participants provided
Lead was widely distributed in the environment from the beginning of the past century until it was removed from most commercial uses in the 1980s. 1, 2 Because of lead's widespread use, average blood lead concentrations among persons in the general population were estimated to be higher than 20 µg/dL in the 1960s 3 and 13 to 15 µg/dL in the late 1970s. 2 In blood, lead has a short clearance half-time of approximately 30 days but collects in bone; in the tibia, the clearance halftime is almost 3 decades. 4 Thus, past lead exposure can influence population health in several ways: through its persistence in the environment, persistent or progressive health effects from remote exposures, 5 or accumulation in, and later release from, bone in older adults who were alive during the period of peak population exposure. Currently, most American adults have low blood lead concentrations, 2 which represent integrated internal (release from bone) and external exposures over an average of the prior 120 days. However, older adults can have moderate to high bone lead concentrations. 6 Tibia lead, with its long clearance half-time, is an estimate of cumulative dose from past exposures. 6 The trabecular bone tissue in the patella is more biologically active and, with a clearance half-time of 3 to 5 years, is an estimate of the bioavailable bone lead pool. 7, 8 Because the metabolism of lead in bone is similar to that of calcium, 9 bone lead can serve as an endogenous source of internal exposure, [10] [11] [12] particularly associated with accelerated demineralization in osteoporosis or aging, 11, [13] [14] [15] resulting in subsequent risk of deposition in critical target organs. 16 To date, studies of bone lead concentrations have focused on populations in Boston, Massachusetts, or Mexico City, Mexico, with no diversity within studies by race/ ethnicity, gender, or socioeconomic status  RESEARCH AND PRACTICE  written informed consent and were paid $50 at each visit.
Data Collection
Data were collected at the study clinic in the following order: neurobehavioral testing, blood pressure, height, weight, spot urine collection, structured interview, and a 10-mL blood specimen by venipuncture. We utilized data from all 3 visits in a cross-sectional analysis. Demographics, medications, tobacco and alcohol histories, blood lead concentrations, and genotypes were from the first visit; tibia lead concentrations, dietary intake, and physical activity were from the second visit; and patella lead concentrations were from the third visit.
Laboratory Methods
Blood lead concentrations were measured with anodic stripping voltammetry (ESA Laboratories, Chelmsford, Massachusetts). 33 We used 109 Cd-induced K-shell x-ray fluorescence to measure tibia and patella lead concentrations in units of micrograms of lead per gram of bone mineral (µg/g), at the midtibia shaft and left-center patella. 34, 35 Because of a growing literature that suggests the toxicokinetics of lead may be modified by genetic polymorphisms, 36, 37 we also evaluated associations with 2 genes thought relevant to deposition or release of lead or calcium from bone: apolipoprotein E, APOE, and vitamin D receptor, VDR (by using 2 restriction enzymes, Bsm I and Fok I). [38] [39] [40] [41] Genotyping was performed in the laboratory of the Malaria Institute in the Bloomberg School of Public Health by standard methods.
38,42
Diet and Physical Activity
We assessed dietary intake with the Block Dietary Questionnaire (Block 98.2, Berkeley Nutrition Services, Berkeley, California), and we calculated nutritional intake estimates based on the National Health and Nutrition Examination Survey III and US Department of Agriculture food intake databases by using DIETSYS software (National Cancer Institute, Bethesda). We used the Yale Physical Activity Survey 43 to assess physical activity in 5 categories (work, yard work, caretaking, exercise, recreation) as frequency per week, duration of activity per time, and seasonal variation.
We then derived standard metrics (8 indices and 2 additional measures), including an energy expenditure summary index, total time summary index, and vigorous-activity index score.
Statistical Analysis
The primary goals of this cross-sectional analysis were to (1) describe differences in lead concentrations in blood, tibia, and patella by gender, race/ethnicity, and SES; (2) evaluate correlates of the 3 lead concentration biomarkers (lead in blood, tibia, and patella) with linear regression; and (3) examine the effect modification of these relations by important potential moderators, such as age, gender, race/ethnicity, physical activity, dietary intake, and genetic polymorphisms. By comparing and contrasting associations with lead concentrations in these 3 pools with different biology and kinetics, we sought to understand the biology underlying gender, race/ethnicity, and SES differences.
Because the distribution of results was skewed in the sample, we natural logarithm (ln)-transformed blood lead concentrations to reflect a more normal distribution before we regressed them on the covariates. The adequacy of the ln-transformation was examined with residual distributions. To facilitate the interpretation of results, we present the back-transformed parameter estimates from the analysis of the ln-transformed sample distributions. The resulting parameter estimates estimated ratios of the median sample distributions across predictor-level units.
Measurement of bone lead concentrations with 109 Cd-induced K-shell x-ray fluorescence can produce negative point estimates when the true bone lead concentration is close to zero. 44 Negative values were particularly common for patella lead concentrations; 30.9% of the samples had values that were less than or equal to zero. We thus used Tobit regression 45, 46 with left truncation at 0 µg/ We used Stata version 8 statistical software (Stata Corp, College Station, Texas) to separately model blood, tibia, and patella lead concentrations. We used multiple linear regression to adjust estimates for potential confounding by conditioning on observed covariates including body mass index (BMI; weight in kilograms divided by height in meters squared), tobacco and alcohol consumption, oral corticosteroid use, postmenopausal hormone use, other relevant medication use, and lifestyle and other risk factors for bone mineral loss (e.g., specific medical conditions, dietary history, physical activity, age, gender, race/ethnicity). Variables were retained in the final models if they were (1) known to be important based on prior studies, (2) significant predictors (P < .05) of lead biomarkers, (3) a confounder (based on a 10% change in regression coefficients), or (4) an effect modifier of the relations of interest. Formal tests of effect modification were performed by comparing improvement in model fit in nested models with and without appropriate crossproduct terms.
We used generalized estimating equations to simultaneously model and directly compare predictors of tibia and patella lead concentrations in the same models while accounting for within-participant correlations of the measurements. 47, 48 Bone lead concentrations were first z-transformed so that concentrations could be compared on the same scale. These models included an indicator variable for bone site and cross-product terms between this indicator variable and predictors of interest (e.g., age, gender, race/ ethnicity). In these models, significant crossproducts would indicate that the association of predictor variables with bone lead concentrations differed for tibias and patellae. We used examination of distributions, residuals, partial residual plots, and variance inflation factors to evaluate the assumptions of linear regression and goodness of fit. 49 We also evaluated potential nonlinearity by inclusion of quadratic terms in the linear regression models (retained if P < .05). Wealth was defined as the total dollar value of household assets plus total household income from visit 1. Time spent for each activity on the checklist was multiplied by an intensity (kcal/min) and was summed over all activities to create a total energy expenditure index for each participant. The frequency score was multiplied by the duration score to create a vigorous activity index score.
RESULTS

Description of Study Participants
The 1140 study participants included 53 
Predictors of Blood Lead Concentrations
In adjusted analyses, on average, participants who were female, had higher BMI, had higher dietary vitamin D or calcium supplement intake, and had a higher Yale vigorous activity index had lower ln-transformed blood lead concentrations (Table 3 , model 1). By contrast, current smokers, those with higher tibia lead concentrations, those who consumed alcoholic beverages in the past month, and those who had a higher Yale energy index had higher ln-transformed blood lead concentrations (Table 3 , model 1). Patella lead concentrations were not associated with blood lead concentrations in adjusted models without (P > .10) or with (P > .30) tibia lead concentrations in the model. The median blood lead concentration was 41% lower for women than for men (P < .01), 0.7% higher for every 1-µg/g increase in tibia lead concentrations, 0.5% lower for every 1-unit increase in the Yale vigorous activity index, and 0.1% higher for each 100-kilocalorie per week increase in the Yale energy index.
We next examined effect modification by potential moderators of the relations between ln-transformed blood lead concentrations and selected covariates (using model 1; Table 3 ). The relations between gender and blood lead concentrations were modified by the Yale vigorous activity index and race/ethnicity (Table 3 , models 2 and 3, respectively). The male-female differences in adjusted median blood lead concentrations were different for Whites and African Americans (P = .04), with magnitudes of gender differences of 49% and 27%, respectively (derived from combining parameter estimates from model 3). There was also a gender difference in the relation of the Yale vigorous activity index with blood lead concentrations (P = .02); median blood lead concentrations declined 0.06% per unit increase in the index for men, but declined 0.8% per unit increase in women. Finally, hormone replacement therapy use in women was associated with 37% lower blood lead concentrations (P < .01; Table 3 , model 4).
Predictors of Tibia Lead Concentrations
In adjusted analyses, on average, participants who were older, African American and had a higher Yale energy index, higher daily dietary vitamin D intake, and lower daily dietary calcium intake had higher tibia lead concentrations (Table 4 , model 1). The average adjusted tibia lead concentrations among  RESEARCH AND PRACTICE  Note. All race/ethnicity groups were included (including African American admixture and others).
a P values reflect evaluation of differences by race/ethnicity from t statistics for continuous variables or from the χ 2 test for binary and categorical variables. Time spent for each activity on the checklist was multiplied by an intensity (kcal/min) and was summed over all activities to create a total energy expenditure index for each participant. e The frequency score was multiplied by the duration score to create a vigorous activity index score.
African Americans were 3.5 µg/g higher than among Whites (P < .01).
We next examined effect modification by potential moderators on the relations between tibia lead concentrations and selected covariates (using model 1). The relation between age and tibia lead concentrations was modified by gender (Table 4 , model 2). The slope relating average tibia lead concentrations and age was 0.3 µg/g per year lower among women than among men (P = .03). The relation between self-reported diabetes status and tibia lead concentrations was also modified by race/ethnicity (P < .01; Table 4 , model 3). On average, participants who reported diabetes had lower tibia lead concentrations than did those who did not; however, African Americans who reported diabetes had the highest average tibia lead concentrations: 6.5 µg/g higher than among African Americans without diabetes, and 8.7 µg/g higher than among Whites with diabetes.
Predictors of Patella Lead Concentrations
The proportion of women with negative patella lead values was almost twice that of men (29% vs 16%; data in this section not shown). In adjusted analyses, on average, participants who were older, male, wealthier, and who reported oral corticosteroid medication use had higher patella lead concentrations (data not shown). In evaluation of effect modification, the relation between gender and patella lead concentrations was modified by the APOE ε4 allele (P = .04). Mean patella lead concentrations among women without the APOE ε4 allele were approximately 11.8 µg/g lower than among men without the APOE ε4 allele; similarly, patella lead concentrations among men with the APOE ε4 allele were, on average, 5.0 µg/g lower than among men without the allele. However, patella lead concentrations among women with the allele were only 2.4 µg/g higher than among women without the allele.
Direct Comparison of Predictors of Patella and Tibia Lead Concentrations
In the simultaneous models, relations of gender, race/ethnicity, and the Yale energy index differed by bone site (each P < .001). Specifically, there was a larger patella-tibia bone lead concentration difference for men than for women, mainly because of the higher patella lead concentrations among men. In addition, there was a larger tibiapatella bone lead concentration difference for African Americans than for Whites, mainly because of higher tibia lead concentrations among African Americans. Finally, tibia lead concentrations increased with increasing Yale energy index, whereas patella lead concentrations very slightly declined.
DISCUSSION
In our large, population-based study of older adults in an urban setting with diversity by gender, race/ethnicity, and SES, we made observations that allowed us to draw several new inferences concerning the population burden of lifetime cumulative lead exposure; the factors that influence bone lead deposition and release; gender, race/ethnicity, and SES differences in lead dose; and the implications of these complex toxicokinetics for lead-related health outcomes with aging. Importantly, contrasting associations of predictor variables of patella lead concentrations with those of tibia lead concentrations allow hypotheses to be generated regarding cumulation and clearance of bone lead burden over time, which has important implications for health.
Differences by Race/Ethnicity
African Americans had higher tibia lead concentrations than did Whites, and this could Note. ln = natural logarithm. Blood lead concentrations (µg/dL) were ln-transformed. Models were controlled for wealth (defined as the total dollar value of household assets plus total household income from visit 1 [in $10 000]) and selfreported history of kidney disease (yes vs no). This model was confined to women only.
not be explained entirely by differences in SES (education and wealth) or other factors, suggesting that African Americans had higher cumulative lead doses from decades of higher environmental exposures. Notably, we may have underestimated the true tibia lead difference by race/ethnicity, because of the possible underrepresentation of African American men in the study. 33 The higher current tibia lead concentrations among African Americans were likely because of their larger lifetime cumulative exposures, rather than differential bone kinetics by race/ethnicity.
The kinetic issues are best evaluated in the more metabolically active patella, 7,8,50-52 and we believe that differential recent release of lead from bone by race/ethnicity is unlikely because (1) race/ethnicity was not associated with patella lead concentrations and (2) there was no effect modification by race/ethnicity on relations of patella lead concentrations with blood lead concentrations. Furthermore, in models of patella lead concentrations, the associations of age, oral corticosteroid use, gender, and the APOE-gender interaction, and in models of blood lead concentrations, the hormone replacement therapy and physical activity associations can all be interpreted as likely explained by bone-demineralization issues with aging. Use of hormone replacement therapy was not associated with patella lead concentrations. The contrasting blood and patella associations could be caused by the relative amounts of lead in bone and blood, which differed by a factor of 200 to 1000 (for example, 400 times for 5 µg/dL in blood, 10 µg/g in bone, 5 L average blood volume, and 10 kg average dry skeletal mass). Thus, a relatively small release of lead from patella could change blood lead concentrations but would not change patella lead concentrations significantly. However, for logistical and budgetary reasons, lead concentrations in blood, tibias, and patellae were measured at different visits, so associations among them, particularly between blood lead concentrations and patella lead concentrations, could have been influenced by the timing of the measurements.
Differences by Age
Tibia lead concentrations were higher with increasing age. This could have been caused by either a cohort effect, because environmental lead concentrations were much higher in the past, or cumulation with age, or both. Because (1) the level of environmental lead exposure in the general population has been declining since the 1980s, 2 (2) the estimated clearance half-time of lead from tibias is approximately 30 years, 8 and (3) the turnover rate of bone mineral in tibias is much slower than in other bones, 51, 52 we concluded that tibia lead concentrations likely were most reflective of lifetime cumulative dose, most of which occurred decades ago. Increasing age was also associated with higher patella lead concentrations. In addition, patella lead concentrations were lower, on average, than tibia concentrations; there were many more negative values; the proportion of negative patella lead values was almost twice as large for women as for men; and the relation of gender with bone lead concentrations differed by bone lead site (in the simultaneous modeling).
Taken together, we believe these findings offer clues about the relative clearance of lead and bone mineral from trabecular bone  RESEARCH AND PRACTICE  with increasing age. Bone mineral density, particularly in trabecular bone such as patellae, is known to decline with age after the peak bone mass is achieved at age 18 to 25 years. 51, 53 Our findings suggest that bone mineral may be more rapidly lost from patellae than lead itself, because bone mineral is the denominator in the bone lead concentration. This could occur, for example, if lead were not distributed homogeneously in bone, particularly if it were at higher concentrations in periosteal bone. We did not observe associations between the 3 lead biomarkers and VDR and APOE genotypes, in contrast to findings from occupational studies. 38, 54 This may be because of lower concentrations of lead in all tissues in nonoccupational studies. However, in adjusted analysis of patella lead concentrations, there was evidence of effect modification by APOE genotype on relations of gender with patella lead concentrations. The APOE ε4 allele is associated with lower bone mineral density and higher bone turnover rates 40, 55 ; our findings may suggest that among men, the allele was associated with lead loss that exceeded bone mineral loss, but among women, the allele was associated with bone mineral loss that exceeded lead loss, as might be expected.
The racial/ethnic difference in tibia lead concentrations was consistent with historical blood lead concentration data in national samples, which have shown important differences by race/ethnicity. 56 Furthermore, the race/ethnicity-diabetes interaction suggests that tibia lead concentrations were highest in African Americans with diabetes, a combination of 3 risk factors that could contribute to disparities in these important racial/ethnic-associated health outcomes. An implication of our findings is that the racial/ ethnic differences in chronic disease outcomes reported in prior studies may have resulted from unmeasured confounding by differences in cumulative lead dose. However, it can be difficult to "separate" the effect of race/ethnicity from cumulative lead dose in health studies. 64, 65 Implications for Health
The findings have implications for population aging. For example, a proportion of what has been termed "normal cognitive aging" may be caused, at least in part, by cumulative lead dose. 58 However, there is no population surveillance of cumulative lead burden among US adults. Use of lead in gasoline peaked in 1969, but the magnitude of the public health implications of the coming collision of population aging-both in terms of numbers and ages attained-with peak lead dosing in early life and midlife, is not understood. Determining how lead will contribute to the coming epidemic of neurodegenerative disease, cognitive decline, and dementia [66] [67] [68] should be a major public health priority. Furthermore, screening and clinical and public health interventions may be especially warranted in the high-risk groups identified in this study (e.g., African Americans, women). We conclude that there are large and important differences in lead biomarkers by gender, race/ethnicity, and several additional factors (e.g., physical activity, dietary intake) that could influence the kinetics of these measures. African Americans have significantly higher current body burdens of lead, likely because of sustained higher ongoing lead exposures over decades. With disease occurrence and bone demineralization with age, women and African Americans would be at higher risk of a number of adverse lead-related health outcomes as they age. The extent to which the differential lifetime cumulative lead dose contributes to observed differences in health status by race/ethnicity needs to be investigated, as do possible interventions to prevent lead-related health outcomes with aging. Human Participant Protection
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